Clinical Trial: TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC

U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07658833) titled 'TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC' on May 29.

Brief Summary: The safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma (HCC) require further in-depth study. This research aims to evaluate the safety, clinical efficacy and prognostic factors of TACE and/or HAIC combined with targeted immunotherapy for hepatocellular carcinoma.

We are going to compare and analyze local tumor response, survival outcomes, prognostic fa...